Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors.

about

Model-based optimization of G-CSF treatment during cytotoxic chemotherapy.

P2860

Q47657705-48A5301C-999C-40C2-A816-B49379CA8265

P2860

Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors.

Item

http://www.wikidata.org/entity/Q38613025

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Pegfilgrastim for the preventi ...... in patients with solid tumors.

@en

type

Item

label

Pegfilgrastim for the preventi ...... in patients with solid tumors.

@en

prefLabel

Pegfilgrastim for the preventi ...... in patients with solid tumors.

@en

P1476

Pegfilgrastim for the preventi ...... in patients with solid tumors

@en

P2093

Romano Danesi

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpatient oncology clinic.

Factors associated with hospital length of stay among cancer patients with febrile neutropenia

A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer.

Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II tr

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.

Efficacy and tolerability of chemotherapy with modified dose-dense TCF regimen (TCF-dd) in locally advanced or metastatic gastric cancer: final results of a phase II trial.

A phase II trial of dose-dense neoadjuvant gemcitabine, epirubicin, and albumin-bound paclitaxel with pegfilgrastim in the treatment of patients with locally advanced breast cancer.

Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity

Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.

Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.

P304

1799-1817

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712598.2015.1101063

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-10-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26488491

http://www.w3.org/2001/XMLSchema#string

P921

chemotherapy-induced febrile neutropenia

Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors.

about

P2860

P2860

Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921